Lipocine (NASDAQ:LPCN) Upgraded to Buy by StockNews.com

StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN) from a hold rating to a buy rating in a research report released on Friday morning.

Lipocine Trading Up 0.5 %

Shares of Lipocine stock traded up $0.02 during midday trading on Friday, reaching $4.41. The company had a trading volume of 40,621 shares, compared to its average volume of 54,213. The stock has a fifty day simple moving average of $6.94 and a 200 day simple moving average of $5.53. Lipocine has a 1-year low of $2.31 and a 1-year high of $11.79. The company has a market capitalization of $23.58 million, a price-to-earnings ratio of -2.58 and a beta of 1.12.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $0.66 earnings per share (EPS) for the quarter. The firm had revenue of $7.62 million for the quarter. Sell-side analysts expect that Lipocine will post -1 earnings per share for the current year.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP purchased a new stake in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.